Xenon Pharmaceuticals
XENE · NASDAQ
$36.27+$1.19 (+3.39%)TodayMarket closed ·
Prev close $35.08
About XENE
- Employees
- 364
- Headquarters
- Vancouver, British Columbia
- Listed
- Oct 17, 2014
- Sector
- Health Care
- Industry
- Biotechnology
- Website
- xenon-pharma.com
Leadership
| Name | Title | Since |
|---|---|---|
| Dawn Svoronos | — | — |
| Ian Mortimer | — | 2013 |
| Thomas Kelly | — | — |
| Darren Cline | — | — |
| Christopher Kenney | — | — |
| Andrea Difabio | — | — |
| Gillian Cannon | — | — |
| Steven Gannon | — | — |
| Elizabeth Garofalo | — | — |
| Justin Gover | — | — |
| Patrick Machado | — | — |
| Gary Patou | — | — |
Revenue by product and region
Fiscal year ended Mar 31, 2020: $7.08M total revenue
By product
- Collaboration Revenue [Member]$7.08M100.0%
- Collaboration Revenue [Member]$5.76M81.4%
- Collaboration Revenue [Member]$1.23M17.4%
- Collaboration Revenue [Member]$83.00K1.2%
Suppliers and customers
Price correlation is over one year: 1 means the stocks move together, -1 opposite
| Company | Relationship | Correlation |
|---|---|---|
| Pacira Biosciences PCRX | Supplier and customer | 0.38 |
| Neurocrine Biosciences NBIX | Supplier and customer | -0.19 |
| Darktrace DARK.L | Supplier | -0.37 |
| Flexion Therapeutics, Inc. FLXN | Supplier and customer | -0.78 |
| Icah School of Medicine at Mount Sinai | Supplier and customer | — |
Similar companies
Companies in the same industry as Xenon Pharmaceuticals
Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.